| 1 |
Wang Z, Yang M, Chen X, Xiao R, Dong Y, Chu M, Song G, Wang Y. Polypharmacology of ambroxol in the treatment of COVID-19. Biosci Rep 2023;43. [PMID: 36651548 DOI: 10.1042/BSR20221927] [Reference Citation Analysis]
|
| 2 |
Bihariesingh-Sanchit R, Bansie R, Ramdhani N, Mangroo R, Bustamente D, Diaz E, Fung A Foek C, Thakoer I, Vreden S, Choudhry Z, van 't Wout AB, Diavatopoulos DA, Nierich AP. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname. mBio 2023;:e0337922. [PMID: 36815780 DOI: 10.1128/mbio.03379-22] [Reference Citation Analysis]
|
| 3 |
Kandula UR, Tuji TS, Gudeta DB, Bulbula KL, Mohammad AA, Wari KD, Abbas A. Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. J Blood Med 2023;14:159-87. [PMID: 36855559 DOI: 10.2147/JBM.S397722] [Reference Citation Analysis]
|
| 4 |
Romera Martínez I, Bueno Cabrera JL, Domingo-Morera JM, López Aguilar JC, Villegas Da Ros C, García Erce JA, Sáez Serrano I, Flores Ballester E, Maglio LA, Arbona Castaño C, Sola Lapeña C, Guerra Domínguez L, Berberana Fernández M, Madrigal Sánchez ME, Rubio Batllés M, Pérez-Olmeda M, Ramos-Martínez A, Velasco-Iglesias A, Avendaño-Solá C, Duarte RF. Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma. Vox Sang 2023. [PMID: 36734378 DOI: 10.1111/vox.13406] [Reference Citation Analysis]
|
| 5 |
Barie PS, Brindle ME, Khadaroo RG, Klassen TL, Huston JM. Omicron, Long-COVID, and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. Surg Infect (Larchmt) 2023;24:6-18. [PMID: 36580648 DOI: 10.1089/sur.2022.274] [Reference Citation Analysis]
|
| 6 |
Pirofski LA. COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic. Clin Microbiol Infect 2023;29:130-2. [PMID: 36343900 DOI: 10.1016/j.cmi.2022.10.033] [Reference Citation Analysis]
|
| 7 |
Franchini M, Casadevall A, Joyner MJ, Focosi D. WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel) 2023;13. [PMID: 36676084 DOI: 10.3390/life13010134] [Reference Citation Analysis]
|
| 8 |
Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, Focosi D, Casadevall A, Joyner MJ. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open 2023;6:e2250647. [PMID: 36633846 DOI: 10.1001/jamanetworkopen.2022.50647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 9 |
Bloch EM, Sullivan DJ, Shoham S, Tobian AAR, Casadevall A, Gebo KA. The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox. mBio 2022;13:e0286222. [PMID: 36314809 DOI: 10.1128/mbio.02862-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Cognasse F, Hamzeh-Cognasse H, Rosa M, Corseaux D, Bonneaudeau B, Pierre C, Huet J, Arthaud CA, Eyraud MA, Prier A, Duchez AC, Ebermeyer T, Heestermans M, Audoux-Caire E, Philippot Q, Le Voyer T, Hequet O, Fillet AM, Chavarin P, Legrand D, Richard P, Pirenne F, Gallian P, Casanova JL, Susen S, Morel P, Lacombe K, Bastard P, Tiberghien P. Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. EBioMedicine 2023;87:104414. [PMID: 36535107 DOI: 10.1016/j.ebiom.2022.104414] [Reference Citation Analysis]
|
| 11 |
Focosi D, McConnell S, Casadevall A. The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. Drug Resist Updat 2022;65:100882. [PMID: 36260961 DOI: 10.1016/j.drup.2022.100882] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 12 |
Shoham S, Focosi D. Limitations on PassItOn Design and Execution Should Temper Negative Conclusions. Chest 2022;162:e282-e283. [DOI: 10.1016/j.chest.2022.07.030] [Reference Citation Analysis]
|
| 13 |
Belem WF, Liu CH, Hu YT, Burnouf T, Lin LT. Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2). Viruses 2022;14. [PMID: 36366517 DOI: 10.3390/v14112419] [Reference Citation Analysis]
|
| 14 |
Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022;13:e0175122. [PMID: 36135380 DOI: 10.1128/mbio.01751-22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Focosi D, Franchini M. Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe. Life 2022;12:1704. [DOI: 10.3390/life12111704] [Reference Citation Analysis]
|
| 16 |
Laner-plamberger S, Lindlbauer N, Weidner L, Gänsdorfer S, Weseslindtner L, Held N, Lauth W, Zimmermann G, Kern JM, Föttinger F, Ombres L, Jungbauer C, Rohde E, Grabmer C. SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability. Diagnostics 2022;12:2567. [DOI: 10.3390/diagnostics12112567] [Reference Citation Analysis]
|
| 17 |
Grubovic Rastvorceva RM, Useini S, Stevanovic M, Demiri I, Petkovic E, Franchini M, Focosi D. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial. Life (Basel) 2022;12. [PMID: 36295001 DOI: 10.3390/life12101565] [Reference Citation Analysis]
|
| 18 |
Adan H, Harb D, Hazari K, Abdelkareem W, Khan FN, Zouaoui M, Raouf M, Elsawy D, Azar AJ, Khamis AH, Ammar A. Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study. BMC Pregnancy Childbirth 2022;22. [DOI: 10.1186/s12884-022-05043-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 19 |
DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity 2022:S1074-7613(22)00500-3. [PMID: 36182669 DOI: 10.1016/j.immuni.2022.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Joyner MJ, Pirofski LA. Convalescent Plasma for Covid-19. N Engl J Med 2022;387:955. [PMID: 36069882 DOI: 10.1056/NEJMc2208338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, Focosi D, Casadevall A, Joyner MJ. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review.. [DOI: 10.1101/2022.08.03.22278359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Gammon R, Katz LM, Strauss D, Rowe K, Menitove J, Benjamin RJ, Goel R, Borge D, Reichenberg S, Smith R. Beyond COVID-19 and lessons learned in the United States. Transfus Med 2023;33:6-15. [PMID: 35918741 DOI: 10.1111/tme.12896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Qian Z, Zhang Z, Ma H, Shao S, Kang H, Tong Z. The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. Front Immunol 2022;13:964398. [DOI: 10.3389/fimmu.2022.964398] [Reference Citation Analysis]
|
| 24 |
Belcari G, Conti A, Mazzoni A, Lanza M, Mazzetti P, Focosi D. Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia. Life (Basel) 2022;12:1098. [PMID: 35888185 DOI: 10.3390/life12071098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Franchini M, Focosi D, Percivalle E, Beccaria M, Garuti M, Arar O, Pecoriello A, Spreafico F, Greco G, Bertacco S, Ghirardini M, Santini T, Schiavulli M, Stefania M, Gagliardo T, Sammartino JC, Ferrari A, Zani M, Ballotari A, Glingani C, Baldanti F. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Viruses 2022;14:1443. [DOI: 10.3390/v14071443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Burnouf T, Gathof B, Bloch EM, Bazin R, de Angelis V, Patidar GK, Rastvorceva RMG, Oreh A, Goel R, Rahimi-levene N, Hindawi S, Al-riyami AZ, So-osman C. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins against SARS-CoV-2. Transfusion Medicine Reviews 2022. [DOI: 10.1016/j.tmrv.2022.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 27 |
Focosi D, Casadevall A. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg Infect Dis 2022;28:1083. [PMID: 35450567 DOI: 10.3201/eid2805.220191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Franchini M, Glingani C, Donno G, Lucchini G, Beccaria M, Amato M, Castelli GP, Bianciardi L, Pagani M, Ghirardini M, Puma G, Presciuttini B, Costantino MT, Frigato M, Crosato V, Tiecco G, Mulè A, Papalia DA, Inglese F, Spreafico F, Garuti M, Pecoriello A, Cervi G, Greco G, Galavotti V, Santini T, Berselli A, Montalto C, Bertoletti R, Bellometti SA, Capuzzo E, Benazzi D, Grisolia G, Pajola F, Stradoni R, Zani M, Verzola A, Codeluppi V, Vesentini S, Bellocchio E, Candini M, Ambrosi G, Carandina F, Scarduelli C, Reggiani A, Casari S, On Behalf Of Convalescent Plasma Study Group. Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience. Life (Basel) 2022;12. [PMID: 35330170 DOI: 10.3390/life12030420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
